Key Publications for DAS181 for the treatment of Influenza

  • Marjuki H. Mishin VP, Chesnokov AP, De La Cruz JA, Fry AM, Villanueva J, Gubareva LV.  An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza. A Virus Subtype H7N9 and Protects Mice From Lethality, J Infect Dis. 2014 Apr 1.

Key publications for DAS181 for the treatment of Parainfluenza Virus in Immunocompromised PatientsGuzmán-Suarez, BB, Buckley, MM,

  • Gilmore, ET, Vocca, E, Moss, R, Marty, FM, Baden, LR, Issa, NC, Koo S. Clinical Potential of DAS181 for Treatment of Parainfluenza-3 Infections in Transplant Recipients, Transplant Infectious Disease, 2012

Key Publications for LILRB

  • van der Touw, W, Chen, HM, Pan, PY & Chen, SH 2017, , Cancer Immunology, Immunotherapy, vol. 66, no. 8, pp. 1079-1087. LILRB receptor-mediated regulation of myeloid cell maturation and function​

Key Publications for allogenic CAR NK/δγ-T

  • Simona Sivori, Raffaella Meazza, Concetta Quintarelli, Simona Carlomagno, Mariella Della Chiesa, Michela Falco, Lorenzo Moretta, Franco Locatelli, Daniela Pende. J Clin Med. 2019 Oct 16;8(10):1702. NK Cell-Based Immunotherapy for Hematological Malignancies

Key Publications for oncolytic vaccinia virus

  • Yu F, Hong B, Song X. A T-cell Engager-armed Oncolytic Vaccinia Virus to Target the Tumor Stroma. Cancer Transl Med. 2017 June; 3(4):122.
Go to Top